Startup profile for Komodo Health: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Komodo Health funding, valuation and investors

Healthcare Map — real-world clinical data platform for life sciences and payers.

Keep track of Komodo Health

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series E

$220M · March 2021

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$270M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

growth · New York, New York

Investors in latest funding

Lead: Tiger Global Management

Other: Andreessen Horowitz , Coatue

Sources: latest funding Last verified: 2026-07-25

Overview

Komodo Health operates the Healthcare Map, aggregating de-identified patient journey data from across the US healthcare system for pharma, payers, and life-sciences analytics. Use cases include market analytics, patient finding, outcomes research, and commercial strategy. Andreessen Horowitz led a $50M Series C in January 2020; Tiger Global led a $220M Series E in March 2021.

Why Komodo Health is interesting

Komodo's longitudinal claims map covers 330M+ patient journeys — a16z led Series C, then Tiger led a $220M Series E as pharma and payers bet on real-world evidence at scale.

Product & use cases

Healthcare Map links de-identified medical and pharmacy claims into longitudinal patient journeys — queryable for epidemiology, market sizing, HCP targeting, and outcomes analysis.

  • Pharma commercial analytics and patient finding
  • Payer population health and cost modeling
  • Real-world evidence for drug development
  • Healthcare market sizing and trend analysis

Key facts

  • Series E (Mar 2021): $220M led by Tiger Global — Businesswire
  • Series C (Jan 2020): $50M led by a16z — Komodo press
  • Healthcare Map — 330M+ patient journeys per company

Funding history (newest first)

Series E

2021-03 $220M

Source: https://www.businesswire.com/news/home/20210322005000/en/

Series C

2020-01 $50M

Source: https://www.komodohealth.com/press/series-c

Investors in our directory

Funds linked from Komodo Health's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz Tiger Global Management Coatue

Competitive landscape

Edge: Scale of longitudinal US healthcare data with modern analytics interface — among largest commercial RWE datasets.

Healthcare data is fragmented and regulated. Komodo competes with IQVIA's scale and newer consortium models like Truveta. Differentiation depends on data freshness, coverage, and analytics UX for life-sciences buyers.

  • IQVIA incumbent

    Dominant healthcare data and CRO incumbent.

  • Truveta direct

    Health system consortium data platform.

  • HealthVerity adjacent

    Healthcare data linking and analytics.

  • Flatiron (Roche) adjacent

    Oncology-specific real-world data.

Notable stories

  • Komodo raised $220M Series E in March 2021 at peak healthtech valuations — Tiger Global led as pharma RWE demand accelerated during COVID-era drug development.

Industries

Healthtech

FAQs about Komodo Health

Practical answers founders, operators, and investors typically search for.

Healthcare Map platform aggregating de-identified US patient journey data for life sciences and payers.
a16z (/fund/andreessen-horowitz) led Series C; Tiger Global (/fund/tiger-global-management) led $220M Series E; Coatue (/fund/coatue) participated.
Longitudinal de-identified claims data linking patient journeys across providers and pharmacies.
IQVIA is incumbent CRO/data giant; Komodo is newer analytics-native platform.
$270M+ across Series C and E plus earlier rounds.
Pharma, payers, and life-sciences companies.
Yes — HIPAA-compliant de-identified claims data.
March 2021 — $220M.
Arif Nathoo and Web Sun.
No — private as of July 2026.
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.